Public Health Impact of Paxlovid as Treatment for COVID-19, United States

Thumbnail Image

Files

Public_Health_Impact_of_Paxlovid_as_Treatment_for_COVID-19_United_States.pdf (1.85 MB)

Access rights

openAccess
CC BY
publishedVersion

URL

Journal Title

Journal ISSN

Volume Title

A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
This publication is imported from Aalto University research portal.
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
Unless otherwise stated, all rights belong to the author. You may download, display and print this publication for Your own personal use. Commercial use is prohibited.

Authors

Date

2024-02

Department

Department of Computer Science

Major/Subject

Mcode

Degree programme

Language

en

Pages

8

Series

Emerging Infectious Diseases, Volume 30, issue 2, pp. 262-269

Abstract

We evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03–0.59 million) hospitalizations and save US $56.95 billion (95% CI US $2.62–$122.63 billion). In a higher transmission scenario (effective reproduction number of 3), the benefits increase, potentially preventing 0.85 million (95% CI 0.36–1.38 million) hospitalizations and saving US $170.17 billion (95% CI US $60.49–$286.14 billion). Our findings suggest that timely and widespread use of Paxlovid could be an effective and economical approach to mitigate the effects of COVID-19.

Description

Publisher Copyright: © 2024 Centers for Disease Control and Prevention (CDC). All rights reserved.

Keywords

Other note

DOI

10.3201/eid3002.230835

Citation

Bai, Y, Du, Z, Wang, L, Lau, E H Y, Fung, I C H, Holme, P, Cowling, B J, Galvani, A P, Krug, R M & Meyers, L A 2024, 'Public Health Impact of Paxlovid as Treatment for COVID-19, United States', Emerging Infectious Diseases, vol. 30, no. 2, pp. 262-269. https://doi.org/10.3201/eid3002.230835

Permanent link to this item

https://urn.fi/URN:NBN:fi:aalto-202507015368

Collections

[article-cris] Perustieteiden korkeakoulu / SCI